MoonLake Immunotherapeutics Says FDA And EMA Both Unanimously Support Co.'s Proposed Approach For Advancing Its Phase 3 Program Of The Nanobody Sonelokimab In Psoriatic Arthritis
Portfolio Pulse from Benzinga Newsdesk
MoonLake Immunotherapeutics announced that both the FDA and EMA have unanimously supported the company's proposed approach for advancing its Phase 3 program of the nanobody Sonelokimab in treating psoriatic arthritis.
June 10, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MoonLake Immunotherapeutics received unanimous support from both the FDA and EMA for its Phase 3 program of Sonelokimab in psoriatic arthritis, which is a significant regulatory milestone.
The unanimous support from both the FDA and EMA is a strong positive signal for MoonLake Immunotherapeutics' Phase 3 program of Sonelokimab. This regulatory milestone increases the likelihood of successful advancement and potential approval, which is likely to positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100